title: Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein.
abstract: Many studies have demonstrated that intravenously administered bacteria can target and proliferate in solid tumors and then quickly be released from other organs. Here, we employed the tumor-targeting property of Escherichia coli Nissle 1917 to inhibit mouse B16 melanoma and 4T1 breast tumors through the expression of azurin protein. For this purpose, recombinant azurin-expressing E. coli Nissle 1917 was developed. The levels of in vitro and in vivo azurin secretion in the engineered bacterium were determined by immunochemistry. Our results demonstrated that B16 melanoma and orthotopic 4T1 breast tumor growth were remarkably restrained and pulmonary metastasis was prevented in immunocompetent mice. It is worth noting that this therapeutic effect partially resulted from the antitumor activity of neutrophils and lymphocytes due to inflammatory responses caused by bacterial infections. No toxicity was observed in the animal during the experiments. This study indicates that E. coli Nissle 1917 could be a potential carrier to deliver antitumor drugs effectively for cancer therapy.
authors.affiliation: College of Life Science, Hunan Provincial Key Laboratory of Microbial Molecular Biology-State Key Laboratory Breeding Base of Microbial Molecular Biology, Hunan Normal University, Changsha, China.
authors.forename: Yunlei
authors.initials: Y
authors.lastname: Zhang
authors.forename: Youming
authors.initials: Y
authors.lastname: Zhang
authors.forename: Liqiu
authors.initials: L
authors.lastname: Xia
authors.forename: Xiangli
authors.initials: X
authors.lastname: Zhang
authors.forename: Xuezhi
authors.initials: X
authors.lastname: Ding
authors.forename: Fu
authors.initials: F
authors.lastname: Yan
authors.forename: Feng
authors.initials: F
authors.lastname: Wu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001400:Azurin / Q000096:biosynthesis* / Q000235:genetics / Q000627:therapeutic use; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D004926:Escherichia coli / Q000145:classification / Q000235:genetics / Q000378:metabolism; D005260:Female; D005818:Genetic Engineering; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000382:microbiology / Q000628:therapy*; D008546:Melanoma, Experimental / Q000378:metabolism / Q000382:microbiology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids
chemical_list: D000970:Antineoplastic Agents; D001400:Azurin